Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Sacituzumab Govitecan-hziy|DRUG: Eribulin|DRUG: Capecitabine|DRUG: Gemcitabine|DRUG: Vinorelbine
Sponsor: Gilead Sciences